ArticleFrontiers in oncology2022

ERCC1 is a potential biomarker for predicting prognosis, immunotherapy, chemotherapy efficacy, and expression validation in HER2 over-expressing breast cancer.

Yilun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.